Sisram Medical Reports Steady Growth in 2025 Annual Results Driven by Injectables Segment

Sisram Medical Ltd (1696.HK) announced a solid financial performance for the fiscal year ended December 31, 2025, characterized by steady growth in both revenue and profit. A primary catalyst for this expansion was the company’s injectables business, which saw significant momentum following the acceleration of DAXXIFY in the Chinese market. The company also benefited from robust performance across international markets, reflecting disciplined strategic execution throughout the year. These audited consolidated results highlight Sisram's successful focus on high-growth segments and effective geographic diversification. Management attributed the positive outcome to a clear strategic roadmap and the initial commercial success of its product portfolio in China. Overall, the results underscore the company's resilient business model and its ability to deliver sustainable value in the global medical technology sector.

Sources:prnewswire.comstockinvest.ustirto.idintelmarketresearch.comnatlawreview.comnews.futunn.com